Serum leukocyte cell-derived chemotaxin-2 (Lect-2) levels in osteoarthritis patients

Year 2024, Volume: 49 Issue: 4, 1014 - 1021, 30.12.2024

Adil Furkan Kılıç , Fatih Baygutalp , Mestan Şahin , Lale Duysak , Zafer Bayraktutan , Yunus Kuralay

https://doi.org/10.17826/cumj.1532416

Abstract

Purpose: An association between the complimentary system and osteoarthritis is becoming more apparent. Lect-2 protein acts as a regulator of immunological and inflammatory responses. This study aims to determine the levels of leukocyte cell-derived chemotaxin-2 (Lect-2) in patients with osteoarthritis.
Materials and Methods: The study included 38 osteoarthritis patients and 36 healthy controls. ESR, WBC, serum CRP and Lect-2 levels were measured both in patients and controls.
Results: ESR and serum CRP levels were significantly higher in patients compared to controls. The mean Lect-2 level in osteoarthritis patients (14.2±4.8 ng/mL) was significantly lower compared to the healthy control group (56.3±20.7 ng/mL). ROC analysis revealed that serum LECT-2 level was a significant parameter in determining patients from healthy controls. Cut off value was ≤24.8 ng/mL with a high AUC (0.990).
Conclusion: The significant reduction in Lect-2 levels in osteoarthritis patients suggests its potential role in disease pathogenesis. This finding may contribute to understanding the immunological aspects of osteoarthritis and could potentially serve as a biomarker for disease progression. Further studies with larger patient populations are needed to validate these findings and explore the therapeutic implications of Lect-2 in osteoarthritis management.

Keywords

Lect-2, Osteoarthritis, Immune system

Osteoartrit hastalarında serum lökosit hücre kaynaklı kemotaksin-2 (Lect-2) düzeyleri

Abstract

Amaç: Komplemantar sistem ile osteoartrit arasındaki ilişki giderek daha belirgin hale gelmektedir. Lect-2 proteini, immünolojik ve inflamatuar yanıtların düzenleyicisi olarak görev yapar. Bu çalışmanın amacı, osteoartrit hastalarında lökosit hücre kaynaklı kemotaksin-2 (Lect-2) düzeylerini belirlemektir.
Gereç ve Yöntem: Çalışmaya 38 osteoartrit hastası ve 36 sağlıklı kontrol grubu dahil edildi. Hasta ve kontrol grubunda sedimentasyon, beyaz küre, serum CRP ve Lect-2 düzeyleri ölçüldü.
Bulgular: Hastalarda ESR ve serum CRP düzeyleri kontrol grubuyla karşılaştırıldığında anlamlı derecede yüksekti. Osteoartrit hastalarında ortalama Lect-2 düzeyi (14.2±4.8 ng/mL) sağlıklı kontrol grubuna (56.3±20.7 ng/mL) göre anlamlı derecede düşük bulundu. ROC analizi serum LECT-2 düzeyinin hasta ile sağlıklı ayrımı yapmada önemli bir parametre olduğunu ortaya koydu. Kesim değeri yüksek AUC (0,990) ile ≤24,8 ng/mL idi.
Sonuç: Osteoartrit hastalarında Lect-2 düzeylerinin belirgin şekilde düşük olması, bu molekülün hastalık patogenezinde potansiyel rolünü göstermektedir. Bu bulgu, osteoartritin immünolojik yönlerinin anlaşılmasına katkı sağlayabilir ve hastalık progresyonunda bir biyobelirteç olarak kullanılabilir. Bu bulguların doğrulanması ve Lect-2'nin osteoartrit tedavisindeki olası rolünün araştırılması için daha geniş hasta popülasyonlarıyla yapılacak ileri çalışmalara ihtiyaç vardır.

Keywords

: İmmün sistem, Lect-2, osteoartrit

Ethical Statement

The study acquired the necessary ethical board permission from the Ethics Board for Scientific Research of the Medical Faculty of the University of Ataturk, as stated in Decision No. 2024/247.

References

• Yang CZ, Zhang YY, Zheng M. Soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in synovial fluid are correlated with disease severity of knee osteoarthritis. Clin Biochem. 2011;44:1094-6.
• Chen D, Shen J, Zhao W, Wang T, Han L, Hamilton JL et al. Osteoarthritis: toward a comprehensive understanding of pathological mechanism. Bone Res. 2017;5:1-13.
• de Oliveira PSS, Cardoso PRG, de Paula Silva SK, Duarte ALBP, da Rosa MM, de Melo Rêgo MJB et al. High serum levels of galectins 1 and 4 in osteoarthritis patients. Clin Biochem. 2023;116:11-5.
• Yao Q, Wu X, Tao C, Gong W, Chen M, Qu M et al. Osteoarthritis: pathogenic signaling pathways and therapeutic targets. Signal Transduct Target Ther. 2023;8:56.
• Xia B, Chen D, Zhang J, Hu S, Jin H, Tong P. Osteoarthritis pathogenesis: a review of molecular mechanisms. Calcif Tissue Int. 2014;95:495-505.
• Toegel S, Bieder D, André S, Altmann F, Walzer SM, Kaltner H et al. Glycophenotyping of osteoarthritic cartilage and chondrocytes by RT-qPCR, mass spectrometry, histochemistry with plant/human lectins and lectin localization with a glycoprotein. Arthritis Res Ther. 2013;15:R147.
• Zheng R, Zhang Y, Zhang K, Yuan Y, Jia S, Liu J. The complement system, aging, and aging-related diseases. Int J Mol Sci. 2022;23:8689.
• Wang Q, Xu F, Chen J, Xie YQ, Xu SL, He WM. Serum leukocyte cell-derived chemotaxin 2 (LECT2) level is associated with osteoporosis. Lab Med. 2023;54:106-11.
• Zhu MH, Liu YJ, Li CY, Tao F, Yang GJ, Chen J. The emerging roles of leukocyte cell-derived chemotaxin-2 in immune diseases: From mechanisms to therapeutic potential. Front Immunol. 2023;14:1158083.
• Ikeda D, Ageta H, Tsuchida K, Yamada H. iTRAQ-based proteomics reveals novel biomarkers of osteoarthritis. Biomarkers. 2013;18:565-72.
• Mishra A, Behura A, Mawatwal S, Kumar A, Naik L, Mohanty SS et al. Structure-function and application of plant lectins in disease biology and immunity. Food Chem Toxicol. 2019;134:110827.
• Liu-Bryan R, Terkeltaub R. Emerging regulators of the inflammatory process in osteoarthritis. Nat Rev Rheumatol. 2015;11:35-44.
• Struglics A, Okroj M, Swärd P, Frobell R, Saxne T, Lohmander LS et al. The complement system is activated in synovial fluid from subjects with knee injury and from patients with osteoarthritis. Arthritis Res Ther. 2016;18:223.
• Assirelli E, Pulsatelli L, Dolzani P, Mariani E, Lisignoli G, Addimanda O et al. Complement expression and activation in osteoarthritis joint compartments. Front Immunol. 2020,11:535010.
• Okumura A, Saito T, Otani I, Kojima K, Yamada Y, Ishida‐Okawara A et al. Suppressive role of leukocyte cell–derived chemotaxin 2 in mouse anti–type II collagen antibody–induced arthritis. Arthritis Rheum. 2008;58:413-21.
• Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med. 2000;133:635-46.
• Remmerie A, Scott CL. Macrophages and lipid metabolism. Cell Immunol. 2018;330:27-42.
• Wei G, Lu K, Umar M, Zhu Z, Lu WW, Speakman JR et al. Risk of metabolic abnormalities in osteoarthritis: a new perspective to understand its pathological mechanisms. Bone Res. 2023;11:63.
• Slowik V, Apte U. Leukocyte cell‐derived chemotaxin‐2: it's role in pathophysiology and future in clinical medicine. Clin Transl Sci. 2017;10:249.
• Molnar V, Matišić V, Kodvanj I, Bjelica R, Jeleč Ž, Hudetz D et al. Cytokines and chemokines involved in osteoarthritis pathogenesis. Int J Mol Sci. 2021;22:9208.
• Hsueh M-F, Önnerfjord P, Kraus VB. Biomarkers and proteomic analysis of osteoarthritis. Matrix Biol. 2014;39:56-66